Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$84.85 USD
+2.71 (3.30%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $84.84 -0.01 (-0.01%) 5:08 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AXSM 84.85 +2.71(3.30%)
Will AXSM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should Know
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
Other News for AXSM
Axsome Therapeutics price target lowered by $2 at BofA, here's why
Decoding 9 Analyst Evaluations For Axsome Therapeutics
Axsome Therapeutics: Stable Auvelity Growth and Coverage Amid New GPO Contract
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Moderna (MRNA) and Axsome Therapeutics (AXSM)